Cadence Pharmaceuticals Reports Third Quarter 2009 Financi...(which speak only as of the date hereof. ...),Health

Date:11/5/2009

which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contact:    William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                Phone : 858-436-1400

                           CADENCE PHARMACEUTICALS, INC.
                           (a development stage company)
                        CONDENSED STATEMENTS OF OPERATIONS
                                    (unaudited)

                          Three Months Ended          Nine Months Ended
                             September 30,              September 30,
                          ------------------          -----------------
                          2009          2008          2009         2008
                          ----          ----          ----         ----
    Operating expenses:
      Research and
       development     $4,924,778   $10,241,943   $15,144,099   $32,463,211
      Sales and
       marketing        2,608,441       664,143     4,330,695     2,175,120
      General and
       administrative   3,762,851     2,754,064     9,549,203     8,323,996
      Other                  (944)          509       412,141        28,766
                             ----           ---       -------        ------
        Total
         operating
         expenses      11,295,126    13,660,659    29,436,138    42,991,093
                       ----------    ----------    ----------    ----------

    Loss from
     operations       (11,295,126)  (13,660,659)  (29,436,138)  (42,991,093)

    Other (
'/>"/>
SOURCE  Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 
Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery